You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Foundayo™ (orforglipron) be used in people with hepatic impairment?
Orforglipron is not recommended for use in people with severe hepatic impairment. No dosage modification of orforglipron is recommended in people with mild or moderate hepatic impairment.
See important safety information, including boxed warning, in the attached prescribing information.
Orforglipron Use in People With Hepatic Impairment
Orforglipron is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).1
No dosage modification of orforglipron is recommended in patients with mild or moderate hepatic impairment (Child-Pugh Class A and B, respectively).1
Orforglipron Pharmacokinetics
Orforglipron is metabolized primarily via hepatic cytochrome P450 3A4 (CYP3A4) to several oxidative metabolites. These oxidative metabolites are excreted into the intestinal lumen.1
The pharmacokinetics of orforglipron after a single oral 0.8 mg dose was evaluated in patients with mild, moderate, and severe hepatic impairment (Child-Pugh Class A, B, and C, respectively) and in subjects with normal hepatic function.1
Orforglipron exposure was similar in participants with mild hepatic impairment and normal hepatic function.1
Orforglipron area under the curve from time zero to infinity (AUC[0-∞]) increased by 1.7-fold and 4.6-fold in participants with moderate and severe hepatic impairment, respectively, compared to participants with normal hepatic function.1
Maximum plasma concentration (Cmax) in participants with moderate and severe hepatic impairment was similar to Cmax in participants with normal hepatic function.1
Enclosed Prescribing Information
Reference
1Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: September 16, 2026